Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Revenue (2016 - 2020)

KalVista Pharmaceuticals' Revenue history spans 7 years, with the latest figure at $3.8 million for Q2 2020.

  • For Q2 2020, Revenue rose 30.69% year-over-year to $3.8 million; the TTM value through Jan 2021 reached $3.8 million, down 67.57%, while the annual FY2025 figure was -$5.8 million, 111.57% down from the prior year.
  • Revenue for Q2 2020 was $3.8 million at KalVista Pharmaceuticals, up from $1.6 million in the prior quarter.
  • Across five years, Revenue topped out at $5.6 million in Q4 2018 and bottomed at $96000.0 in Q3 2017.
  • The 5-year median for Revenue is $2.3 million (2018), against an average of $2.3 million.
  • The largest annual shift saw Revenue plummeted 90.15% in 2017 before it surged 4145.61% in 2018.
  • A 5-year view of Revenue shows it stood at $197000.0 in 2016, then skyrocketed by 472.08% to $1.1 million in 2017, then soared by 396.18% to $5.6 million in 2018, then fell by 29.9% to $3.9 million in 2019, then decreased by 2.45% to $3.8 million in 2020.
  • Per Business Quant, the three most recent readings for KALV's Revenue are $3.8 million (Q2 2020), $1.6 million (Q1 2020), and $3.9 million (Q4 2019).